Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that its PGDx Elio Plasma Resolve liquid biopsy assay has received CE marking.

The in vitro diagnostic uses next-generation sequencing to detect single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, and microsatellite instability in circulating cell-free DNA isolated from plasma samples to guide therapy selection for cancer patients. PGDx also markets a tissue-based version of the test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.